Impact Biomedical Inc. (IBO) · Nov 3, 2026 · Acquisition

Impact Biomedical merger vote set after F-4 clears SEC

F-4 effective — Stockholder vote scheduled for November 13, 2026

Impact Biomedical’s merger with Zoar clears SEC registration and moves to a November 13 stockholder vote, but closing remains conditional.

Impact Biomedical is trying to pivot from a science-and-licensing platform into a pharmaceutical company through its proposed combination with Zoar, which develops and manufactures active pharmaceutical ingredients, orphan drugs, and contract-manufacturing services. The merger process was already public, and the F-4 had been filed in September with SEC effectiveness, shareholder approval, NYSE American listing approval, and other closing conditions still outstanding.

The transaction cleared an important procedural hurdle, but this is process progress rather than business validation. The SEC declared Zoar’s Form F-4 effective on October 23, allowing the definitive proxy/prospectus to be mailed. The stockholder meeting is now scheduled for November 13, 2026. 〔0〕

The filing does not materially reduce the core closing risk. Stockholders still must approve the deal, NYSE American must approve the listing, and other conditions must be satisfied or waived. 〔1〕 There are also no new operating results, deal economics, financing details, or evidence here that Zoar’s pharmaceutical business will deliver the expected benefits.

Bottom line: This advances the merger toward its decisive vote, so it is modestly constructive versus the prior status. But because the milestone was expected and closing remains conditional, it does not yet rewrite Impact’s business story.

What to watch next

Stockholder vote, November 13

Original filing on SEC EDGAR

Impact Biomedical merger vote set after F-4 clears SEC | IBO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.